Literature DB >> 26002723

Combined thrombus aspiration and recanalization in treating Budd-Chiari syndrome with inferior vena cava thrombosis.

Yu-Fei Fu1, Hao Xu2, Qian Wu3, Qing-Qiao Zhang2, Yan-Feng Cui2, Ning Wei4.   

Abstract

PURPOSE: To investigate the feasibility, safety, and effectiveness of combined thrombus aspiration and inferior vena cava (IVC) recanalization for Budd-Chiari syndrome (BCS) patients with IVC thrombosis.
MATERIALS AND METHODS: From March 2011 to October 2014, 17 consecutive BCS patients with IVC thrombosis [male 13, female 4 (mean age 52.6 ± 8.4 years, range 43-72 years)] treated by combined thrombus aspiration and IVC recanalization were enrolled in this retrospective study. An 8F guiding catheter was used as the aspiration catheter. During the treatment, the aspiration catheter was placed from the right femoral vein to the IVC thrombi, and a 20-ml syringe was connected with the aspiration catheter for thrombus aspiration. IVC recanalization was performed after thrombus aspiration. Data on technical success, clinical success, and follow-up were analyzed.
RESULTS: Technical success was achieved in all patients. After thrombus aspiration, 12 patients had no visible thrombi on IVC venography, while 5 patients were shown to have the IVC mural thrombi. Afterwards, 13 patients were treated by IVC balloon dilation, and 4 patients were treated by IVC stent insertion. No patient experienced dyspnea after treatment. The average IVC pressure decreased from 29.8 ± 3.4 cmH2O to 8.6 ± 2.1 cmH2O (P < 0.001). Clinical success was achieved in all patients. The average follow-up period was 15.3 ± 11.6 months (range 2-44 months). Long-term IVC patency was achieved in 15 of 17 patients.
CONCLUSION: Combined thrombus aspiration and IVC recanalization can be a safe and effective method for BCS patients with IVC thrombosis.

Entities:  

Keywords:  Aspiration; Budd–Chiari syndrome; Inferior vena cava; Thrombosis

Mesh:

Year:  2015        PMID: 26002723     DOI: 10.1007/s11547-015-0554-9

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  14 in total

1.  Direct imaging of deep-vein thrombosis with magnetic resonance imaging.

Authors:  A R Moody
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

2.  Treatment of Budd-Chiari syndrome with urokinase following predilation in patients with old inferior vena cava thrombosis.

Authors:  P-X Ding; Y-D Li; X-W Han; G Wu; S-F Shui; Y-L Wang
Journal:  Radiol Med       Date:  2010-10-06       Impact factor: 3.469

3.  Retrieval stent filter: treatment of Budd Chiari syndrome complicated with inferior vena cava thrombosis--initial clinical experience.

Authors:  Xin-Wei Han; Peng-Xu Ding; Yong-Dong Li; Gang Wu; Ming-Hua Li
Journal:  Ann Thorac Surg       Date:  2007-02       Impact factor: 4.330

4.  Endovascular treatment of surgically implanted arterial graft thrombosis by using manual aspiration thrombectomy.

Authors:  Hakan Önder; Levent Oguzkurt; Ugur Özkan; Kamil Gürel; Serkan Gür; Cagatay Andic; Güven Tekbas
Journal:  Diagn Interv Radiol       Date:  2013 Jul-Aug       Impact factor: 2.630

5.  Applicability of different endovascular methods for treatment of refractory Budd-Chiari syndrome.

Authors:  Yong Gao; Shiyuan Chen; Chaowen Yu
Journal:  Cell Biochem Biophys       Date:  2011-11       Impact factor: 2.194

6.  Management of pulmonary embolism with rheolytic thrombectomy.

Authors:  Lisa Ferrigno; Robert Bloch; Judson Threlkeld; Thomas Demlow; Raman Kansal; Riyad Karmy-Jones
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

7.  Endovascular treatment of acute and subacute iliofemoral deep venous thrombosis by using manual aspiration thrombectomy: long-term results of 139 patients in a single center.

Authors:  Levent Oğuzkurt; Uğur Ozkan; Oner Gülcan; Nihal Koca; Serkan Gür
Journal:  Diagn Interv Radiol       Date:  2012-02-16       Impact factor: 2.630

8.  Anticoagulation with warfarin for Budd-Chiari syndrome with chronic inferior vena cava thrombosis: an initial clinical experience.

Authors:  Xin-Hong He; Wen-Tao Li; Wei-Jun Peng; Yong-Dong Li; Hua-Qiao Tan
Journal:  Ann Vasc Surg       Date:  2010-10-29       Impact factor: 1.466

9.  Clinical outcomes of warfarin anticoagulation after balloon dilation alone for the treatment of Budd-Chiari syndrome complicated by old inferior vena cava thrombosis.

Authors:  Jingmin Sun; Qingqiao Zhang; Hao Xu; Qianxin Huang; Bin Shen; Maoheng Zu; Yuming Gu
Journal:  Ann Vasc Surg       Date:  2014-07-09       Impact factor: 1.466

10.  Combined clot fragmentation and aspiration in patients with acute pulmonary embolism.

Authors:  Guering Eid-Lidt; Jorge Gaspar; Julio Sandoval; Félix Damas de los Santos; Tomás Pulido; Héctor González Pacheco; Carlos Martínez-Sánchez
Journal:  Chest       Date:  2008-01-15       Impact factor: 9.410

View more
  5 in total

1.  Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome.

Authors:  Zhong-Ke Chen; Jing Fan; Chi Cao; Yu Li
Journal:  Radiol Med       Date:  2018-05-31       Impact factor: 3.469

2.  Good Clinical Outcomes in Budd-Chiari Syndrome with Hepatic Vein Occlusion.

Authors:  Xinxin Fan; Kai Liu; Yuan Che; Shikai Wang; Xingjiang Wu; Jianmin Cao; Jieshou Li
Journal:  Dig Dis Sci       Date:  2016-05-25       Impact factor: 3.199

3.  Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.

Authors:  Yan-Feng Cui; Yu-Fei Fu; De-Chun Li; Hao Xu
Journal:  Hepatol Int       Date:  2015-10-23       Impact factor: 6.047

4.  Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes.

Authors:  Aboelyazid Elkilany; Mohamed Alwarraky; Timm Denecke; Dominik Geisel
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

5.  Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis.

Authors:  Gauri Mukhiya; Xueliang Zhou; Xinwei Han; Dechao Jiao; Gaurab Pokhrel; Yahua Li; Sita Pokhrel
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.